Omni Bio Pharmaceutical Inc

Omni Bio Pharmaceutical — Investor Presentation (March 2012)

25 slides from Omni Bio Pharmaceutical's investor presentation, Mar 20, 2012

  1. Slide 1: Controlling Inflammation and Autoimmunity

    Slide 1: Controlling Inflammation and Autoimmunity

    Controlling Inflammation and Autoimmunity March 2012 Pharmaceutical, Inc. (OTC:OMBP) 1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements. The forward-looking statements in this presentation are based on information available to us as of the date any such statements are made and w

  3. Slide 3: Alpha1-Antitrypsin Protects against Neutrophilic Inflammation

    Slide 3: Alpha1-Antitrypsin Protects against Neutrophilic Inflammation

    Molecular Medicine Alpha1-Antitrypsin Protects inst Neutrophilic Inflammation Page 865 OF iB

  4. Slide 4: Alpha-1-Antitrypsin (AAT)

    Slide 4: Alpha-1-Antitrypsin (AAT)

    Alpha-1-Antitrypsin (AAT) Prescribed for emphysema in AAT deficient patients - $500M market (Grifols, Baxter, CSL Behring, Kamada) Administered once a week by infusion One of best safety records of any biological FDA approved - and marketed for > 20 years 4 The body's natural anti-inflammatory circu

  5. Slide 5: New Indications for AAT Therapy: A Broad Spectrum of Inflammatory and Immunological Diseases

    Slide 5: New Indications for AAT Therapy: A Broad Spectrum of Inflammatory and Immunological Diseases

    New Indications for AAT Therapy: A Broad Spectrum of Inflammatory and Immunological Diseases Type 1 Diabetes Lewis et al., PNAS 2005 Strom et al., PNAS 2005 Ma et al., Diabetologia 2010 Graft Versus Host Disease (Bone-marrow Transplantation) Marcondes et al., Blood 2011 Tarawa et al., PNAS 2011 Acut

  6. Slide 6: Alpha-1-Antitrypsin (AAT) for treatment of multiple new indications

    Slide 6: Alpha-1-Antitrypsin (AAT) for treatment of multiple new indications

    Alpha-1-Antitrypsin (AAT) (for treatment of multiple new indications) The Problem - Limited Supply and High Cost AAT is derived by purification from human blood (plasma) The Solution - Make a Synthetic Protein Multiple companies are working on creating synthetic AAT using recombinant technology 6

  7. Slide 7: Omni Solution: Synthetically Produced Human Fc-AAT

    Slide 7: Omni Solution: Synthetically Produced Human Fc-AAT

    N full-length human AAT hinge Omni Solution: Synthetically Produced Human Fc-AAT AAT AAT Fc Fc Fusion Protein -S-S- -S-S- Fc fragment of immunoglobulin 7

  8. Slide 8: Components for Making Synthetic Fc-AAT

    Slide 8: Components for Making Synthetic Fc-AAT

    AAT Immunoglobulin G Fc -S-S- -S-S- -S-S- -S-S- Fc Components for Making Synthetic Fc-AAT 8

  9. Slide 9: Fusion Protein - Fc-AAT

    Slide 9: Fusion Protein - Fc-AAT

    Fc -S-S- -S-S- Fc 100 to 1000 times more potent than plasma-derived AAT One-step Purification Novel Molecule - Patent Application Filed Fusion Protein - Fc-AAT 9

  10. Slide 10: Production and Purification of Fc-AAT

    Slide 10: Production and Purification of Fc-AAT

    pCAG.neo/huIgG1aFc AAT Gene Affinity Purification Fc-AAT Cell Culture one-step purification Production and Purification of Fc-AAT 10

  11. Slide 11: Comparison of Plasma-Derived AAT with Fc-AAT on Endotoxin-Induced IL-1beta

    Slide 11: Comparison of Plasma-Derived AAT with Fc-AAT on Endotoxin-Induced IL-1beta

    Comparison of Plasma-Derived AAT with Fc-AAT on Endotoxin-Induced IL-1beta (human adherent blood monocytes) endotoxin 500 250 125 5 2.5 1.25 0.65 0 100 200 300 400 500 Plasma-derived AAT (µg/mL) Synthetic Fc-AAT (µg/mL) 350-fold difference 100-fold difference Interleukin-1^ (pg/mL) 11

  12. Slide 12: Plasma-Derived AAT Reduces Acute Myocardial Infarct Size

    Slide 12: Plasma-Derived AAT Reduces Acute Myocardial Infarct Size

    Plasma-Derived AAT Reduces Acute Myocardial Infarct Size Myocardial Infarct Size Myocardial Infarct Size Plasma-derived AAT at 2 mg/mouse/day x 7 days Toldo et al., J Mol Cell Cardiol, 51:244, 2011 12 P=0.001

  13. Slide 13: Fc-AAT Reduces Acute Myocardial Infarct Size

    Slide 13: Fc-AAT Reduces Acute Myocardial Infarct Size

    Fc-AAT Reduces Acute Myocardial Infarct Size (at 40X lower dose given once) (at 40X lower dose given once) (at 40X lower dose given once) P=0.006 13 Fc-AAT at 50 µg/mouse - single dose

  14. Slide 14: Possible Mechanisms of Enhanced Potency of Fc-AAT

    Slide 14: Possible Mechanisms of Enhanced Potency of Fc-AAT

    Enhanced ease and speed of purification Reduced inactivation of AAT Less oxidation No polymerization Prolonged plasma and tissue half-life Targeting of AAT to myeloid cells (which have an Fc receptor) Possible Mechanisms of Enhanced Potency of Fc-AAT 14

  15. Slide 15: Plan for Clinical Development of Synthetic Fc-AAT

    Slide 15: Plan for Clinical Development of Synthetic Fc-AAT

    Plan for Clinical Development of Synthetic Fc-AAT Scale-up Synthesis Demonstration Batch cGMP Drug Product Preclinical Safety/Tox IND Human Safety Type 1 Diabetes Graft vs. Host Disease (GVHD) Myocardial Infarction Purity Efficacy Safety 100 grams Stability Characterize Impurities 1 Kilo Timetable 2

  16. Slide 16: Enbrel is a Successful Model for the Clinical Development of Fc-AAT

    Slide 16: Enbrel is a Successful Model for the Clinical Development of Fc-AAT

    Fc-AAT Naturally occurring circulating protein Bound to Fc Produced in CHO cells Affinity Purification Enbrel Naturally occurring circulating protein Bound to Fc Produced in CHO cells Affinity Purification Enbrel is a Successful Model for the Clinical Development of Fc-AAT 16

  17. Slide 17: Type 1 Diabetes Market Opportunity

    Slide 17: Type 1 Diabetes Market Opportunity

    Type 1 Diabetes Market Opportunity Annually, more than 15,000 children and 15,000 adults are diagnosed with Type 1 diabetes.* The rate of Type 1 diabetes incidence among children under the age of 14 is estimated to increase by 3% annually worldwide.* *Source: Juvenile Diabetes Research Foundation (J

  18. Slide 18: GVHD Market Opportunity

    Slide 18: GVHD Market Opportunity

    GVHD Market Opportunity 2010 - GVHD global market estimated at $261 million with estimated CAGR of 11.3%* 2018 - GVHD global market estimated at $615 million based on estimated CAGR* *Source: GlobalData - "Graft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 20

  19. Slide 19: Acute Myocardial Infarction Market Opportunity

    Slide 19: Acute Myocardial Infarction Market Opportunity

    Acute Myocardial Infarction Market Opportunity Heart disease is the leading cause of death for both men and women In 2010 - estimated cost of heart disease in the US is $316 billion * Source: Center for Disease Control and Prevention 19

  20. Slide 20: Inflammatory Bowel Disease Market Opportunity

    Slide 20: Inflammatory Bowel Disease Market Opportunity

    Inflammatory Bowel Disease Market Opportunity Prevalence rate estimated at 396/100,000 persons in US* Estimated that up to 1.4 million persons in US* Overall healthcare costs of more than $1.7 billion in US* *Source: Center for Disease Control and Prevention 20

  21. Slide 21: Omni Bio - Corporate Information

    Slide 21: Omni Bio - Corporate Information

    Stock Symbol OMBP.OB Closing Stock Price (March 8, 2012) $1.70 52-Week Range $1.00 - $5.50 Shares Outstanding 32.0 million Fully Diluted Shares 46.4 million Estimated Public Float Shares 18.0 million Market Capitalization (March 8, 2012) $54.4 million Fiscal Year-End March 31 Omni Bio - Corporate In

  22. Slide 22: Our Team

    Slide 22: Our Team

    Our Team Chief Executive Officer - James D. Crapo, MD - CEO and Director since February 2011; SAB Member since 2009 - Professor of Medicine-National Jewish Hospital (1996-Present) - Chief, Division of Allergy, Critical Care and Respiratory Medicine-Duke University (1979-1996) - Chairman, Dept of Med

  23. Slide 23: Our Team

    Slide 23: Our Team

    Our Team Chief Financial Officer - Robert C. Ogden, CPA - 20 plus years in senior financial management positions - Significant experience as CFO of NASDAQ and microcap companies - Led two NASDAQ companies to successful strategic buy-outs - Former audit manager with PriceWaterhouseCoopers - BS Commer

  24. Slide 24: Alpha-1-Antitrypsin Program: Scientists and Patents

    Slide 24: Alpha-1-Antitrypsin Program: Scientists and Patents

    CEO: James D. Crapo CFO: Robert C. Ogden Fc-AAT - 2003 and 2011 Patent Applications License pending from University of Colorado Method of Use Patents - 2000-2011 OmniBio Founding Scientist, Omni Bio Chief Scientific Officer, Omni Bio Chair, SAC , Omni Bio University of Michigan Ben Gurion University

  25. Slide 25: Thank you for your interest

    Slide 25: Thank you for your interest

    Thank you for your interest Thank you for your interest! omnibiopharma.com (720) 488-4708 (Corporate & Investor Inquiries) 25

Source: SEC EDGAR · 8-K filed Mar 20, 2012

More decks from Omni Bio Pharmaceutical Inc